NCT05533632 - Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes | Biotech Hunter

Enrollment

104

Participants

Timeline

Start Date

April 25, 2022

Primary Completion Date

January 18, 2024

Study Completion Date

January 18, 2024

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Semaglutide

Participants will receive semaglutide s.c. injection once weekly in a dose escalation manner for 24 weeks.

Trial Locations (3)

Servicios Médicos Godoy Limitada, Santiago, Región Metropolitana

Hospital San Juan de Dios_Santiago, Región Metropolitana, Santiago, Región Metropolitana

Hospital Padre Hurtado, Santiago, Región Metropolitana